This inventor holds 1 USPTO granted patent. Top assignee: Alkahest, Inc.. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Esther Rawner: Patent Work in Retina-Associated Disease Treatment
Introduction
Esther Rawner is an inventor associated with Alkahest, Inc., in San Carlos, California. Her patent work concerns approaches to treating retina-associated diseases, including wet age-related macular degeneration.
Latest Patents
Rawner is credited with 1 patent: “Methods of Improving Retina-Associated Disease Outcome Using CCR3-Inhibitors.” The disclosure describes administering a CCR3 inhibitory agent before an anti-VEGF agent to a person with wet age-related macular degeneration. It also describes giving subsequent anti-VEGF doses less frequently than the recommended schedule. A related method addresses treatment of retina-associated disease with an anti-VEGF agent after prior treatment with a CCR3 inhibitory agent.
Career Highlights
Rawner’s listed patent reflects work on combining CCR3 inhibition with anti-VEGF treatment, with the aim of reducing the frequency of anti-VEGF administration. The patent identifies Alkahest, Inc. as her company affiliation.
Collaborations
Her listed coworkers include Jessica A. Powell and Bartosz Sikorski.
Conclusion
Esther Rawner’s patent contribution focuses on a treatment strategy for retina-associated diseases that pairs CCR3 inhibition with less frequent anti-VEGF dosing.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile